MTP-PE added to chemotherapy did not improve outcomes in metastatic osteosarcoma patients

How to Cite

OrthoEvidence. MTP-PE added to chemotherapy did not improve outcomes in metastatic osteosarcoma patients. ACE Report. 2013;2(7):612. Available from: https://myorthoevidene.com/AceReport/Report/5098

Study Type:Therapy

OE Level Evidence:2

Journal Level of Evidence:N/A

Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group

Cancer. 2009 Nov 15;115(22):5339-48. doi: 10.1002/cncr.24566

Contributing Authors: AJ Chou ES Kleinerman MD Krailo Z Chen DL Betcher JH Healey Conrad EU ML Nieder MA Weiner RJ Wells RB Womer PA Meyers Children's Oncology Group

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

91 patients with metastatic osteosarcoma were randomized to receive a 3-drug treatment of chemotherapy (cisplatin, doxorubicin, and high-dose methotrexate) with or without ifosfamide. Within each group patients were further randomized to either receive liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) or not to determine whether the addition of liposomal MTP-PE to chemotherapy was eff...